Article Details
Retrieved on: 2024-03-10 20:27:05
Tags for this article:
Click the tags to see associated articles and topics
Summary
Galderma's research on nemolizumab, a monoclonal antibody, shows long-term efficacy in treating prurigo nodularis and atopic dermatitis, with data presented at AAD 2024 underlining its potential in dermatology and epidemiology.
Article found on: www.morningstar.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here